EP1003514A4 - CYCLIC AMINES MODULATING THE ACTIVITY OF CHIMIOKIN RECEPTORS - Google Patents

CYCLIC AMINES MODULATING THE ACTIVITY OF CHIMIOKIN RECEPTORS

Info

Publication number
EP1003514A4
EP1003514A4 EP98936920A EP98936920A EP1003514A4 EP 1003514 A4 EP1003514 A4 EP 1003514A4 EP 98936920 A EP98936920 A EP 98936920A EP 98936920 A EP98936920 A EP 98936920A EP 1003514 A4 EP1003514 A4 EP 1003514A4
Authority
EP
European Patent Office
Prior art keywords
chimiokin
receptors
modulating
activity
cyclic amines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98936920A
Other languages
German (de)
French (fr)
Other versions
EP1003514A1 (en
Inventor
Charles G Caldwell
Paul E Finke
Malcolm Maccoss
Laura C Meurer
Sander G Mills
Bryan Oates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800958.2A external-priority patent/GB9800958D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1003514A1 publication Critical patent/EP1003514A1/en
Publication of EP1003514A4 publication Critical patent/EP1003514A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EP98936920A 1997-07-25 1998-07-21 CYCLIC AMINES MODULATING THE ACTIVITY OF CHIMIOKIN RECEPTORS Withdrawn EP1003514A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5375497P 1997-07-25 1997-07-25
US53754P 1997-07-25
GB9800958 1998-01-16
GBGB9800958.2A GB9800958D0 (en) 1998-01-16 1998-01-16 Cyclic amine modulators of chemokine activity
PCT/US1998/014990 WO1999004794A1 (en) 1997-07-25 1998-07-21 Cyclic amine modulators of chemokine receptor activity

Publications (2)

Publication Number Publication Date
EP1003514A1 EP1003514A1 (en) 2000-05-31
EP1003514A4 true EP1003514A4 (en) 2000-10-11

Family

ID=26312958

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98936920A Withdrawn EP1003514A4 (en) 1997-07-25 1998-07-21 CYCLIC AMINES MODULATING THE ACTIVITY OF CHIMIOKIN RECEPTORS

Country Status (5)

Country Link
EP (1) EP1003514A4 (en)
JP (1) JP2002510327A (en)
AU (1) AU8576098A (en)
CA (1) CA2296314A1 (en)
WO (1) WO1999004794A1 (en)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
TR200101155T2 (en) * 1998-11-17 2001-09-21 F. Hoffmann-La Roche Ag 4-Aroil Piperidine CCR-3 Receptor Antagonists III
AU3126700A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6331545B1 (en) 1998-12-18 2001-12-18 Soo S. Ko Heterocycyclic piperidines as modulators of chemokine receptor activity
CA2347909A1 (en) 1998-12-18 2000-06-22 Joseph B. Santella, Iii N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
PE20001420A1 (en) * 1998-12-23 2000-12-18 Pfizer CCR5 MODULATORS
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
IL145401A0 (en) 1999-03-24 2002-06-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
CA2371618A1 (en) * 1999-04-28 2000-11-09 Yuji Ishihara Cyclic amide compounds, their production and use
US6689765B2 (en) 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
PL203117B1 (en) * 1999-05-04 2009-08-31 Schering Corp Piperidine derivatives useful as ccr5 antagonists
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
SK286641B6 (en) * 1999-05-04 2009-03-05 Schering Corporation Piperazine derivatives useful as CCR5 antagonists, pharmaceutical compositions comprising them and their use
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
EP1050307A1 (en) * 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
US6472410B1 (en) 1999-06-11 2002-10-29 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
WO2000076513A1 (en) 1999-06-11 2000-12-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6500844B1 (en) 1999-06-11 2002-12-31 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
AU5600100A (en) 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
WO2000076511A1 (en) 1999-06-11 2000-12-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6358979B1 (en) 1999-06-11 2002-03-19 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
AU772321B2 (en) * 1999-06-11 2004-04-22 Merck Sharp & Dohme Corp. N-cyclopentyl modulators of chemokine receptor activity
SE9902987D0 (en) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
PE20010628A1 (en) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd CYCLIC AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE
SE9903544D0 (en) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
EP1219605B1 (en) 1999-10-05 2006-05-10 Takeda Pharmaceutical Company Limited Urea compounds, process for producing the same and use thereof
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) * 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (en) 2000-04-08 2003-12-26 Astrazeneca Ab PIPERIDINE DERIVATIVES, PROCESS FOR THE PREPARATION AND USE OF THESE DERIVATIVES IN THE MANUFACTURE OF MEDICINES
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
EP1526134B1 (en) * 2000-05-26 2008-09-03 Pfizer Limited Triazolyl tropane derivatives as ccr5 modulators
US6667314B2 (en) 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
GB0013060D0 (en) * 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
WO2002002525A2 (en) 2000-06-30 2002-01-10 Bristol-Myers Squibb Pharma Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
TWI227231B (en) * 2000-07-12 2005-02-01 Novartis Ag 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3
GB0017174D0 (en) * 2000-07-12 2000-08-30 Novartis Ag Organic compounds
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
SE0003828D0 (en) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
US6656953B2 (en) 2000-12-06 2003-12-02 Sepracor Inc. 4,4-Disubstituted piperidines, and methods of use thereof
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
ATE466009T1 (en) 2001-03-29 2010-05-15 Schering Corp CCR5 ANTAGONISTS USABLE FOR THE TREATMENT OF AIDS
GB0108099D0 (en) * 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
SE0101322D0 (en) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
DE60209736T2 (en) 2001-07-02 2006-11-02 Astrazeneca Ab PIPERIDINE COMPOUNDS SUITABLE AS MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AU2002326948A1 (en) 2001-09-18 2003-04-01 Bristol-Myers Squibb Company Piperizinones as modulators of chemokine receptor activity
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0103818D0 (en) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
AR041786A1 (en) * 2002-03-15 2005-06-01 Novartis Ag DERIVATIVES OF AZETIDINE AS ANTAGONISTS OF THE CCR-3 RECEIVER, A PROCESS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A MEDICINAL PRODUCT
SE0200844D0 (en) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (en) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US6872826B2 (en) * 2002-03-29 2005-03-29 Schering Corporation Stereoselective alkylation of chiral 2-methyl-4-protected piperazines
TW200409630A (en) 2002-09-12 2004-06-16 Bristol Myers Squibb Co N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
AU2003275257A1 (en) 2002-09-26 2004-04-19 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
AU2003284984B2 (en) * 2002-10-30 2008-10-23 Merck Sharp & Dohme Corp. Gamma-aminoamide modulators of chemokine receptor activity
CN1744899A (en) 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 Piperidine derivatives as CCR5 antagonists
JP4736043B2 (en) * 2003-03-14 2011-07-27 小野薬品工業株式会社 Nitrogen-containing heterocyclic derivatives and drugs containing them as active ingredients
ZA200507806B (en) 2003-03-24 2007-03-28 Actimis Pharmaceuticals Inc 2-phenoxy- and 2-enysulfomamide derivatives with CCR3 antagonistic acitivity for the treatment of asthma and other inflammatory or immunolgical disorders
SE0300957D0 (en) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
EP1619193A4 (en) 2003-04-18 2010-08-11 Ono Pharmaceutical Co Spiropiperidine compound and medicinal use thereof
SE0301369D0 (en) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
KR20060019587A (en) 2003-06-11 2006-03-03 머크 앤드 캄파니 인코포레이티드 Substituted 3-alkyl and 3-alkenyl azetidine derivatives
PL1663966T3 (en) * 2003-09-15 2007-11-30 Novartis Ag 1,3-disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
SE0400208D0 (en) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
EP1889622A4 (en) 2005-05-31 2009-12-23 Ono Pharmaceutical Co Spiropiperidine compound and medicinal use thereof
CA2612325A1 (en) * 2005-06-15 2006-12-28 Anormed Inc. Chemokine receptor binding compounds
CA2615650A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
WO2007049771A1 (en) 2005-10-28 2007-05-03 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
PT1961744E (en) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Basic group-containing compound and use thereof
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
RU2008140144A (en) 2006-03-10 2010-04-20 Оно Фармасьютикал Ко., Лтд. (Jp) NITROGEN CONTAINING HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL PRODUCT INCLUDING SUCH DERIVATIVE AS AN ACTIVE INGREDIENT
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
JP5730871B2 (en) * 2009-07-24 2015-06-10 グラクソスミスクライン エルエルシー Therapeutic compound
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
EP3233077B1 (en) 2014-12-19 2026-05-06 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
CN109069426B (en) 2015-12-14 2021-10-29 X4 制药有限公司 Methods of treating cancer
CN109069486A (en) 2015-12-14 2018-12-21 X4 制药有限公司 The method for the treatment of cancer
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
EP3808748B1 (en) 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as CXCR4 inhibitors
JP6994767B2 (en) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド CXCR4 inhibitor and its use
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN110483490B (en) * 2019-08-29 2023-02-03 苏州汉德创宏生化科技有限公司 Synthesis method of 3- (piperidine-4-yl) oxazolidine-2-ketone and salt thereof
CN115515585A (en) 2020-03-10 2022-12-23 X4 制药有限公司 Methods for treating neutropenia
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494717A1 (en) * 1991-01-10 1992-07-15 Shell Internationale Researchmaatschappij B.V. Piperidine derivatives
EP0630887A1 (en) * 1993-05-24 1994-12-28 Zeneca Limited 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists
EP0673928A1 (en) * 1994-03-18 1995-09-27 Sanofi Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists
WO1997029097A1 (en) * 1996-02-09 1997-08-14 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
EP0903349A2 (en) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
GB9502644D0 (en) * 1995-02-10 1995-03-29 Zeneca Ltd Heterocyclic derivatives
US5789422A (en) * 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494717A1 (en) * 1991-01-10 1992-07-15 Shell Internationale Researchmaatschappij B.V. Piperidine derivatives
EP0630887A1 (en) * 1993-05-24 1994-12-28 Zeneca Limited 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists
EP0673928A1 (en) * 1994-03-18 1995-09-27 Sanofi Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists
WO1997029097A1 (en) * 1996-02-09 1997-08-14 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
EP0903349A2 (en) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9904794A1 *

Also Published As

Publication number Publication date
WO1999004794A1 (en) 1999-02-04
JP2002510327A (en) 2002-04-02
AU8576098A (en) 1999-02-16
CA2296314A1 (en) 1999-02-04
EP1003514A1 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
EP1171122A4 (en) PYRROLIDINES MODULATORS OF THE ACTIVITY OF THE CHIMIOKIN RECEPTOR
EP0751773A4 (en) TOCOLYTIC ANTAGONISTS OF OCEYTOCIN RECEPTORS
DE69837906D1 (en) INSECTICIDES PROTEINTOXIN OF XENORHABUS
DE69619819D1 (en) KNAPSACK SPRAYER
PT1000048E (en) SUBSTITUTED DERIVATIVES OF 1,2,3,4-TETRAHYDROFOLATALENE
NO960884D0 (en) N- (3-benzofuranyl) urea-derivatives
PT754407E (en) LIQUID FORMULATIONS OF 1,2-BENZISOYLAZOLIN-3-ONA
PT921125E (en) DERIVATIVES OF 1,38-TRIAZA-ESPIRO 4,5 DECAN-4-ONA
ID19801A (en) 5'-DEOKSI-SITIDINA
IT1301931B1 (en) CONNECTION OF TREES
FI962499L (en) Improving the effectiveness of herbicides
NO179571C (en) Hoof pad
EP1453470A4 (en) MODULATORS OF RHO C ACTIVITY
FR2758235B1 (en) WATERING APPARATUS
IT244003Y1 (en) TREE OF TREE
DE69710305D1 (en) Derivatives of 4-vinyl-4'-alpha-hydroxyethyl-biphenyl
ATA72694A (en) REPLACEMENT DEVICE OF SPRAY HEADS
DE69709755D1 (en) THE TOP OF BOTTLE-BASED STRAPS
IT1277681B1 (en) HERBICIDE ACTIVITIES ARILTIADIAZOLONI
EP0815220A4 (en) HUMAN AMINE CARRIER
ID23006A (en) 13-DIHIDRO-3 'AZIRIDINO ANTRASIKLINA
UA1629S (en) SET OF FESTONS "VESNYANKA-5"
KR960012307U (en) Balance member of carrier head
ID21408A (en) DURUNAN-DURUNAN N- (4-KARBAMIMIDO-FENIL) -FENILGLISINAMID
UA1498S (en) SET OF LABELS "SUMSKA HOROBYNOVA"

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000225

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000829

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/445 A, 7C 07D 401/06 B, 7C 07D 211/14 B, 7C 07D 409/06 B, 7C 07D 403/04 B, 7C 07D 413/04 B, 7A 61K 31/535 B, 7C 07D 407/04 B, 7C 07D 401/04 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020201